FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595186179> ?p ?o ?g. }

• W2595186179 abstract "Abstract Background: localized ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) was effectively treated with frontline radiotherapy. however it is sometimes associated with radiation-related complications of ocular structures, as well as distant relapse or delayed relapse. Although there are no definitive optimal treatment approaches for these patients, we investigated the results in accordance with frontline treatment modalities for OAML. Patients and methods: 159 patients with biopsy-confirmed primary OAML between 2007 and 2015 were analyzed retrospectively. All the patients were sorted by risk-stratification with Ann-Arbor staging and the tumor, node, metastasis (TNM) staging system, and treatment modalities according to anatomic location, prognosis factors, which were supported by ophthalmologist. Results: first-line radiotherapy had overall survival(OS) of 100%, event-free survival(EFS) of 90%. However frontline-radiotherapy group has 100% of survival with 55% of moderate to severe dry eye syndrome, 37.4% of cataract incidence, 11% of cataract-related operations, and 1% (n=1) of radiation-related blindness. Although 5-year EFS is good in radiotherapy group (90% vs 64% in radiotherapy group vs chemotherapy, p<0.001), most of aggressive factors (young age at diagnosis, conjunctival lesions, Ann Arbor stage I, early T1N0M0 stage, and no distant extranodal metastasis including of bone marrow involvement) showed in radiotherapy group in comparison with chemotherapy group. In subgroup analysis of first-line chemotherapy, rituximab-containing group has more good response of event-free survival (p= 0.041) with tolerable hematologic toxicities compared to frontline radiotherapy group. Conclusion: OAML with localized to conjunctiva alone was treated with frontline-radiotherapy and non-conjuctival lesions treated with chemotherapy. Radiotherapy as first-line is good local control-therapeutic option in patients with localized to conjunctiva alone, but management of radiation-associated complication is concerned troubles. In advanced OAML including of extra-conjunctival lesions, systemic chemotherapy is best options. rituximab-based regimen could be feasible to obtain good disease-free survival and response rate. Table 1. Patient's characteristics between frontline-chemotherapy and radiation group (n= 159) Factors Primary Chemotherapy group(n = 68) Primary Radiation group(n = 91) P-value Gender (male) 37 (54%) 28 (30.8%) 0.003 Age at diagnosis (median, year) 50 43 0.003 involvement of both eyes at diagnosis 22 (32.4%) 23 (25.3%) 0.75 Conjuctival lesion at diagnosis 22 (32.4%) 76 (83.5%) <0.001 Ki-67 on pathologic stain (median, %) 5 4 0.545 Ann-Arbor stage I 23 (66.2%) 3 (96.7%) <0.001 LDH at diagnosis (mg/L) 355 344 0.216 Patients no. with T1N0M0 21 (30.9%) 78 (85.7%) <0.001 Bone marrow involvement 7 (10.3%) 0 (0%) <0.001 Patients no. with N1~N3 staging 10 (14.7%) 0 (0%) <0.001 Patients no. with T0N0M1~2 7 (10.3%) 0 (0%) <0.001 Patients treated with frontline chemotherapy were classified in more aggressive or advanced stage which compare to patients treated with primary radiotherapy statistically. Table 2. Patient's characteristics between Rituximab containing group and non-rituximab in frontline chemotherapy subgroup (n=68) Factors Ritixumab-containing(n = 26) No Rituximab(n = 42) P-value Gender (male) 0.942 Age at diagnosis (median, year) 52 49 0.411 involvement of both eyes at diagnosis 0.057 Conjuctival lesion at diagnosis 0.087 Ki-67 on pathologic stain (median, %) 4 3 0.540 Ann-Arbor stage I 0.532 LDH at diagnosis (mg/L) 353 356 0.782 Patients no. with T1N0M0 0.585 Patients no. with N1~N3 staging 0.659 Patients no. with T0N0M1~2 0.695 There are statistically no differences between patients treated with Rituximab-containing regimen and non-rixuximab in frontline chemotherapy subgroup. Figure 1. *event-free survival / overall survival between primary chemotherapy group and patients with radiotherapy * event: from partial response to progressive disease after completion of primary treatments, or death. Figure 1. *event-free survival / overall survival between primary chemotherapy group and patients with radiotherapy * event: from partial response to progressive disease after completion of primary treatments, or death. Figure 2. *event-free survival between patients with rituximab-containing regimen and without rituximab in subgroup analysis of frontline-chemotherapy group * event: from partial response to progressive disease after completion of primary treatments, or death Figure 2. *event-free survival between patients with rituximab-containing regimen and without rituximab in subgroup analysis of frontline-chemotherapy group * event: from partial response to progressive disease after completion of primary treatments, or death Figure 3. Figure 3. Disclosures No relevant conflicts of interest to declare." @default.
• W2595186179 created "2017-03-23" @default.
• W2595186179 creator A5021692797 @default.
• W2595186179 creator A5034751203 @default.
• W2595186179 creator A5036020306 @default.
• W2595186179 creator A5044372572 @default.
• W2595186179 creator A5055206475 @default.
• W2595186179 creator A5059291757 @default.
• W2595186179 creator A5079417302 @default.
• W2595186179 creator A5084426605 @default.
• W2595186179 creator A5085429434 @default.
• W2595186179 creator A5086415059 @default.
• W2595186179 creator A5086500437 @default.
• W2595186179 date "2015-12-03" @default.
• W2595186179 modified "2023-10-09" @default.
• W2595186179 title "Clinical Manifestations and Treatment Results in Accordance with Frontline Treatment Modalities for Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma (OAML)" @default.
• W2595186179 doi "https://doi.org/10.1182/blood.v126.23.1522.1522" @default.
• W2595186179 hasPublicationYear "2015" @default.
• W2595186179 type Work @default.
• W2595186179 sameAs 2595186179 @default.
• W2595186179 citedByCount "0" @default.
• W2595186179 crossrefType "journal-article" @default.
• W2595186179 hasAuthorship W2595186179A5021692797 @default.
• W2595186179 hasAuthorship W2595186179A5034751203 @default.
• W2595186179 hasAuthorship W2595186179A5036020306 @default.
• W2595186179 hasAuthorship W2595186179A5044372572 @default.
• W2595186179 hasAuthorship W2595186179A5055206475 @default.
• W2595186179 hasAuthorship W2595186179A5059291757 @default.
• W2595186179 hasAuthorship W2595186179A5079417302 @default.
• W2595186179 hasAuthorship W2595186179A5084426605 @default.
• W2595186179 hasAuthorship W2595186179A5085429434 @default.
• W2595186179 hasAuthorship W2595186179A5086415059 @default.
• W2595186179 hasAuthorship W2595186179A5086500437 @default.
• W2595186179 hasConcept C126322002 @default.
• W2595186179 hasConcept C141071460 @default.
• W2595186179 hasConcept C2775934546 @default.
• W2595186179 hasConcept C2776694085 @default.
• W2595186179 hasConcept C2778336483 @default.
• W2595186179 hasConcept C2779338263 @default.
• W2595186179 hasConcept C2780653079 @default.
• W2595186179 hasConcept C509974204 @default.
• W2595186179 hasConcept C71924100 @default.
• W2595186179 hasConceptScore W2595186179C126322002 @default.
• W2595186179 hasConceptScore W2595186179C141071460 @default.
• W2595186179 hasConceptScore W2595186179C2775934546 @default.
• W2595186179 hasConceptScore W2595186179C2776694085 @default.
• W2595186179 hasConceptScore W2595186179C2778336483 @default.
• W2595186179 hasConceptScore W2595186179C2779338263 @default.
• W2595186179 hasConceptScore W2595186179C2780653079 @default.
• W2595186179 hasConceptScore W2595186179C509974204 @default.
• W2595186179 hasConceptScore W2595186179C71924100 @default.
• W2595186179 hasLocation W25951861791 @default.
• W2595186179 hasOpenAccess W2595186179 @default.
• W2595186179 hasPrimaryLocation W25951861791 @default.
• W2595186179 hasRelatedWork W1858370274 @default.
• W2595186179 hasRelatedWork W2015926882 @default.
• W2595186179 hasRelatedWork W2047675552 @default.
• W2595186179 hasRelatedWork W2105446438 @default.
• W2595186179 hasRelatedWork W2136359143 @default.
• W2595186179 hasRelatedWork W2149500145 @default.
• W2595186179 hasRelatedWork W2164532955 @default.
• W2595186179 hasRelatedWork W2361379986 @default.
• W2595186179 hasRelatedWork W2381555712 @default.
• W2595186179 hasRelatedWork W2384805139 @default.
• W2595186179 hasRelatedWork W2385314853 @default.
• W2595186179 hasRelatedWork W2416837632 @default.
• W2595186179 hasRelatedWork W2552920160 @default.
• W2595186179 hasRelatedWork W2557162820 @default.
• W2595186179 hasRelatedWork W2588941455 @default.
• W2595186179 hasRelatedWork W2591685160 @default.
• W2595186179 hasRelatedWork W2625938932 @default.
• W2595186179 hasRelatedWork W2784994214 @default.
• W2595186179 hasRelatedWork W3091607722 @default.
• W2595186179 hasRelatedWork W3092073838 @default.
• W2595186179 isParatext "false" @default.
• W2595186179 isRetracted "false" @default.
• W2595186179 magId "2595186179" @default.
• W2595186179 workType "article" @default.